Loading...
Loading...
Peregrine Pharmaceuticals
PPHM announced today that during the course of preparing
for an end-of-phase II meeting with regulatory authorities and
following recent data announcements from its randomized, double-blind
placebo-controlled Phase II trial of bavituximab in second-line
non-small cell lung cancer, it discovered major discrepancies between
some patient sample test results and patient treatment code
assignments. Due to the double-blind nature of the trial, Peregrine
was not permitted to have access to either patient group assignments
or related product coding information.
As part of the trial's
execution, Peregrine contracted with independent third-party
contractors to execute treatment group assignments and oversee
clinical trial material coding and distribution according to
established procedures. A subsequent review of information has
determined that the source of these discrepancies appear to have been
associated with the independent third-party contracted to code and
distribute investigational drug product.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in